The China flu diagnostic and treatment market is valued at US$3,543.759 million in 2020. The market is estimated to grow at a CAGR of 21.52% to reach a market value of US$13,867.909 million by 2027.
The flu diagnostics and treatment market in China is growing due to the different types of flu outbreaks in China. The demand for flu diagnostics and treatment in China is increasing due to the insufficient flu vaccine supplements in the country. With the growing population, the flu is spreading even more rapidly and causing more harm. The newly emerging influenza A (H1N1) and the expansion of the flu across the nation are a big threat to its citizens.
Inadequate government initiatives
China has not included influenza vaccination in the country’s National Immunization Program (NIP) even though it is the most effective means to prevent infection. The average national vaccination coverage in China is very low amounting to only 1-2 percent during 2004-2014, and there is even a decline in the approval of vaccines for sale by the country’s National Institute for Food and Drug Control (NIFDC). This has been due to the recent scandals that happened in China related to improper vaccines among the elderly population, which is further driving the market growth of flu diagnostic and treatment in China.
The market is projected to get a boost from this as people are losing faith in the safety of domestically produced vaccines. The low coverage of flu vaccines combined with the growing geriatric population in China will further lead to the market growth of flu diagnostics and treatment in the country.
Health concerns and awareness to drive the market
Flu diagnostic and treatment demand is also increasing in China because of increased media and public coverage, increased health campaigns, and improved access to accurate data on influenza spread across the country. The rising coverage of healthcare insurance in urban and rural areas will further induce people to use more healthcare services, thereby driving the market for flu diagnostics and treatment.
The growing infrastructure in China like a better transportation system, airlines, and high-speed rail transport, is further making it easy to spread the virus on a larger scale and in a shorter time across the country. This increases the chances of new viruses being released into the environment, thus positively impacting market growth.
The China flu diagnostic and treatment market has been segmented on the basis of the type of flu, offering, age group, and end-user. The market has been classified on the basis of type A and type B based on the type of flu. By offering, the market has been segmented into diagnostics and therapeutics. The market has been segmented on the basis of the age group of 0-14 years, 15-64 years, and >=65 years. By the end-user, the segmentation has been done based on the hospital laboratory, outpatient clinic, and reference laboratory.
Key Developments
The outbreak of the COVID-19 pandemic initially began in Wuhan, China in 2019, and then spread to major parts of the world. The pandemic resulted in the implementation of strict lockdown and social distancing regulations since China was among the worst-hit regions in the world. Additionally, the region was also affected by an increase in influenza cases during that time. This led to significant developments in the diagnosis and treatment of flu and related illnesses since the COVID-19 virus was also a type of flu. Hence, the market demand for flu diagnosis and treatment in the region increased significantly.
| Report Metric | Details |
|---|---|
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Report Metric | Details |
| Market Size Value in 2020 | US$3,543.759 million |
| Market Size Value in 2027 | US$13,867.909 million |
| Growth Rate | CAGR of 21.52% from 2020 to 2027 |
| Base Year | 2020 |
| Forecast Period | 2022–2027 |
| Forecast Unit (Value) | USD Million |
| Segments Covered | Type of Flu, Offering, Age Group, And End-User |
| Companies Covered | Abbott, Roche Diagnostics China, BD, Thermo Fisher Scientific, 3M, Quidel Corporation |
| Customization Scope | Free report customization with purchase |
Segmentation